Pharmacists’ perspectives and attitudes towards the 2021 down-scheduling of melatonin in Australia using the Theoretical Domains Framework: a mixed-methods study

Abstract

Background In Australia, prescription melatonin became a ‘Pharmacist Only Medicine’ for people over 55 with insomnia from June 2021. However, little is known about pharmacists’ views on melatonin down-scheduling and perceived impacts on practice. Aim To explore Australian community pharmacists’ views on and attitudes towards the down-scheduling of melatonin. Method A convenience sample of community pharmacists and pharmacy interns were recruited. Participants completed a survey capturing demographic and professional practice details, and rated their knowledge, beliefs and attitudes towards melatonin. This was followed by an online semi-structured interview. Interviews were guided by a schedule of questions developed using the Theoretical Domains Framework and explored the perceived role of melatonin, preparation/response to down-scheduling, practice changes and patient interactions. Interviews continued until data saturation and were digitally recorded, transcribed verbatim and analysed using the Framework Approach. Results Twenty-four interviews were conducted with community pharmacists (n = 19) and intern pharmacists (n = 5), all practicing in metropolitan areas. Pharmacists/intern pharmacists welcomed the increased accessibility of melatonin for patients. However, pharmacists perceived a disconnect between the guidelines, supply protocols and pack sizes with practice, making it difficult to monitor patient use of melatonin. The miscommunication of eligibility also contributed to patient-pharmacist tension when supply was denied. Importantly, most participants indicated their interest in upskilling their knowledge in melatonin use in sleep, specifically formulation differences and dosage titration. Conclusion While pharmacists welcomed the down-scheduling of melatonin, several challenges were noted, contributing to pharmacist-patient tensions in practice. Findings highlight the need to refine and unify melatonin supply protocols and amend pack sizes to reflect guideline recommendations as well as better educating the public about the risk-benefits of melatonin.

Community Pharmacists’ Knowledge, Attitudes and the Perceived Safety and Effectiveness of Melatonin Supplements: A Cross-Sectional Survey

“…Community pharmacists can aid in preventing the misuse of OTC drugs, including melatonin, by educating and counselling patients on the proper use of these supplements. Community pharmacists can also monitor for potential drug interactions and advise patients on using OTC drugs in combination with other medications [51][52][53].…”

“…While melatonin is available as an OTC drug in some countries, it is classified as a prescription-only medication in others. Community pharmacists can play an essential role in ensuring its safe use by providing information on appropriate dosing and potential adverse effects and also advising patients on the proper use of melatonin for sleep-related disorders [51][52][53].…”